Effects of Heart Failure and its Pharmacological Management on Sleep
- PMID: 22125571
- PMCID: PMC3223909
- DOI: 10.1016/j.ddmod.2011.02.006
Effects of Heart Failure and its Pharmacological Management on Sleep
Abstract
Heart failure (HF) patients have a high prevalence of disturbed sleep. Optimal pharmacological management of HF includes the use of angiotensin converting enzyme inhibitors and β-blockers, which have been associated with decreased severity of central sleep apnea, which is likely secondary to improvements in cardiac performance. There is also evidence, however, indicating that other pharmacological treatments for HF might adversely affect sleep. This brief review introduces the topic of disturbed sleep in HF and examines the extent to which its standard pharmacological management impacts sleep quality.
References
-
- Levy D, et al. Long-term trends in the incidence of and survival with heart failure. N. Eng. J. Med. 2002;347(18):1397–1402. - PubMed
-
- DeFrances CJ, et al. 2006 National hospital discharge survey. Natl Health Stat. Report. 2008;5:1–20. - PubMed
-
- Lloyd-Jones D, et al. Heart disease and stroke statistics--2010 update: A report from the American Heart Association. Circulation. 2010;121(7):e46–215. - PubMed
-
- Hunt SA, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol. 2009;53(15):e1–e90. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous